Analogous to incidental reports of antiphospholipid antibodies (APL) in earlier coronavirus pandemics, these antibodies have occasionally been reported in COVID-19 (95), albeit of an IgA class, which have not yet been included in the classification criteria of APS (96). Here, CD79A is linked to autoimmune polyendocrinopathy.